Status:
UNKNOWN
Donepezil Treatment of Psychotic Symptoms in Dementia Patients
Lead Sponsor:
Beersheva Mental Health Center
Conditions:
Dementia of Alzheimer Type
Eligibility:
All Genders
65-90 years
Phase:
PHASE3
Brief Summary
Conventional psychotropic medications may be used to treat behavioral disturbances and psychotic symptoms in patients with dementia and they are the drugs of choice for treating delusions and hallucin...
Detailed Description
Criteria for inclusion into the study will be: 1) DSM-IV diagnosis of Dementia of the Alzheimer type with psychotic symptoms such as hallucinations and delusions, aggression/agitation, irritability, a...
Eligibility Criteria
Inclusion
- age: 65-90
- DSM-IV diagnosis of Alzheimer's type dementia
- inclusion of psychotic symptoms such as: hallucinations and delusions, aggression/agitation, irritability and disinhibition calling for adminstration of antipsychotic drugs
- duration of psychotic symptoms of at least 2 weeks before start of treatment
- lack of improvement of psychotic symptoms during perphenazine treatment for at least 3 weeks
Exclusion
- vascular demential
- concurrent Axis I DSM-IV diagnosis (delirium, schizophrenia, delusional disorder and affective disorders)
- significant medical illness (cardiovascular, liver, renal, edocrinal, B12 or folic acid deficience and neurological illnesses)
- drug or alcohol addiction
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00190021
Last Update
September 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beersheva Mental Health Center
Beersheva, Israel